Share This Author
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression‐free survival, and there was no significant difference among the three treatment groups with respect to overall survival.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
RECIST 1.1-Update and clarification: From the RECIST committee.
Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
This article presents several models that allow for the commensurability of the information in the historical and current data to determine how much historical information is used in hierarchical Bayesian methods for incorporating historical data that are adaptively robust to prior information that reveals itself to be inconsistent with the accumulating experimental data.
CT screening for lung cancer: five-year prospective experience.
CT allows detection of early-stage lung cancers andBenign nodule detection rate is high, and results suggest no stage shift.
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
- S. Mandrekar, D. Sargent
- Medicine, BiologyJournal of clinical oncology : official journal…
- 20 August 2009
This work discusses and evaluates various clinical trial designs for the validation of biomarker-guided therapy and suggests that well-designed retrospective analysis from well-conducted prospective RCTs can bring forward effective treatments to marker-defined subgroups of patients in a timely manner.
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience.
A reduction in the frequency and/or the severity of attacks was seen in nearly three-fourths of patients who were offered empirical therapies and the rate of progression to multiple myeloma appears to be comparable to that of monoclonal gammopathy of undetermined significance.
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
- M. Lacy, S. Hayman, S. Rajkumar
- MedicineJournal of clinical oncology : official journal…
- 20 October 2009
The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.
Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer
Sorafenib combined with gefitinib is well tolerated, with promising efficacy in patients with advanced non–small cell lung cancer, and studies to further investigate the significance of the reduction in gefithinib exposure by sorafenIB are warranted.